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Abstract: The purpose of this study was to develop a novel formulation of paclitaxel (PTX) 
that would improve its therapeutic index. Here, we combined a concept of polymer–PTX drug 
conjugate with a concept of polymeric micelle drug delivery to form novel free PTX-loaded 
poly(L-γ-glutamylglutamine) (PGG)–PTX conjugate nanoparticles. The significance of this 
drug formulation emphasizes the simplicity, novelty, and flexibility of the method of forming 
nanoparticles that contain free PTX and conjugated PTX in the same drug delivery system. The 
results of effectively inhibiting tumor growth in mouse models demonstrated the feasibility of 
the nanoparticle formulation. The versatility and potential of this dual PTX drug delivery system 
can be explored with different drugs for different indications. Novel and simple formulations 
of PTX-loaded PGG–PTX nanoparticles could have important implications in translational 
medicines.
Keywords: paclitaxel, polymeric micelle, poly(L-γ-glutamylglutamine)–paclitaxel, 
  nanoconjugate, nanoparticles
Introduction
Paclitaxel (PTX; Bristol-Myers Squibb, New York, NY, USA), which is extracted from 
the bark of the Pacific Yew tree,1 is known as Taxol® (Cremophor–ethanol formulation of 
PTX) and is approved by the US Food and Drug Administration (FDA) for the treatment 
of ovarian cancer, breast cancer, and lung cancer. However, the formulation of PTX has 
a low therapeutic index due to its inability to selectively target tumor tissues and to the 
toxic side effects of the Cremophor–ethanol diluent.2,3 Recently, other formulations have 
been explored for improving the therapeutic response of PTX. Polymeric micelle for-
mulation of PTX is one of the recent formulations and clinical trials are now underway. 
NK105 is one of the polymeric micelle formulations that contains amphiphilic block 
copolymers of poly(ethylene glycol)-modified poly(aspartate) with 4-phenyl-1-butanol 
modification and entrapped PTX.4 Hamaguchi et al reported that NK105 had higher 
antitumor activity than PTX and reduced neurotoxicity in mouse models.4 Results 
of clinical trial studies of NK105 showed that it was well tolerated5 and efficacious 
in patients with gastric cancers.6 Another polymeric micelle formulation of PTX is 
Genexol-PM® (Samyang Pharmaceuticals, Daejeon City, Korea),7 amphiphilic micelle-
forming diblock copolymers of poly(D,L-lactide) and poly(ethylene glycol), and PTX 
incorporated within the core. A Phase I clinical trial study showed that Genexol-PM 
delivered higher PTX drug doses without additional toxicity,8 and it also had a better 
response rate in patients with metastatic breast cancer9 compared with Taxol.10–12 In 
addition to polymeric micelles, polymer–PTX conjugate is another formulation of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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PTX. Several polymer conjugates have been actively pursued 
and extensively reviewed.13,14 Poly(L-glutamic acid)–PTX 
conjugate (CT-2103) was considered one of the most suc-
cessful polymer–PTX conjugates to date.14 CT-2103 was 
investigated in multitrial Phase III studies,15,16 yet it has not 
been approved by the FDA. CT-2103 is currently undergoing a 
Phase III clinical trial in combination with carboplatin against 
chemotherapy-naïve advanced non-small cell lung cancer in 
women with estradiol .25 pg/mL.17 Recent formulations of 
PTX have shown encouraging results.
Previously,  we  developed  a  new  poly-(L-γ-
glutamylglutamine)–paclitaxel nanoconjugate (PGG–PTX).18 
PGG–PTX was demonstrated to be efficacious in antitumor 
activity in vivo and outperformed Abraxane® (Abraxis 
Bioscience, Summit, NJ, USA) (albumin-bound PTX 
nanoparticle) in some mouse models.19   Pharmacokinetics 
and tissue distribution of PGG–PTX resulted in prolonged 
half-life of total taxane, extractable taxanes, and active free 
PTX in both the plasma and tumor compartments compared 
with the Cremophor–ethanol formulation of PTX in BABL/c 
nude mice bearing lung cancer NCI-H460 xenografts.20 We 
speculated that hybridizing polymer–PTX conjugate with 
free PTX would create a novel class of PTX nanoparticle 
formulation and improve the therapeutic index of PTX.
Materials and methods
Materials
PTX was obtained from NuBlocks (Vista, CA, USA). Ethanol 
was purchased from Sigma-Aldrich, St Louis, MO, USA. 
PGG–PTX was synthesized in our laboratory, as described 
previously.18 1H-nuclear magnetic resonance (1H-NMR) 
spectra were recorded at 400 MHz with a JEOL spectrometer 
(JEOL USA Inc., Peabody, MA, USA) at room temperature. 
1H chemical shifts were reported in parts per million (ppm). 
Purified deionized water was prepared by the Milli-Q plus 
system from Millipore (Billerica, MA).
BABL/c nude mice were purchased from   Sino-British 
SIPPR/BK Lab Animal Ltd (Shanghai, China). All the mice 
were acclimated for at least 1 week before experimenta-
tion. All the studies were performed in accordance with the 
approved animal protocols.
Preparation of free PTX-loaded  
Pgg–PTX nanoparticles
The free PTX-loaded PGG–PTX nanoparticles were prepared 
as follows. A solution of free PTX (75 mg) in ethanol 
(5 mg/mL) was added dropwise into a solution of PGG–PTX 
(1 g) in distilled water at a concentration of 25 mg/mL, while 
gently stirring at room temperature. The solution was then 
opened to air overnight (∼15 hours) to allow slow evaporation of 
ethanol and formation of the   nanoparticles. The residual ethanol 
was removed by vacuum distillation with a rotary evaporator. 
The colorless nanoparticle solution was filtered with a 0.45 µm 
pore-sized microfiltration membrane before dynamic light 
scattering (DLS) studies and transmission electron microscopy 
(TEM) studies of particle sizing and before injecting to maxi-
mum tolerated dose (MTD) and efficacy studies.
1h-NMr characterization
To show the PTX-loading characteristics of the PTX-loaded 
nanoparticles, the nanoparticle solution was freeze-dried, 
and the nanoparticles were reconstituted in deuterated water 
(D2O) or deuterated methanol (CD3OD) at room temperature. 
1H-NMR spectra of the free PTX in CD3OD, PGG–PTX 
nanoconjugate in D2O, and PTX-loaded PGG–PTX nanopar-
ticles D2O and CD3OD were recorded on a Varian 400 MHz 
spectrometer (Varian, Palo Alto, CA, USA).
Transmission electron microscopy
The morphologies PGG–PTX nanoconjugate and   PTX-loaded 
PGG–PTX nanoparticles were observed by using a TEM 
H-7000 (Hitachi, Tokyo, Japan), an electron microscope 
operating at an accelerating voltage of 75 kV . Negative staining 
was performed as follows: 1) a drop of sample solution was 
placed onto a copper grid coated with carbon, 2) the sample 
drop was taped with a filter paper to remove surface water 
and air-dried for 5 min followed by the application of 0.01% 
phosphotungstic acid to deposit the micelles on the grid, and 
3) the samples were air-dried before observation.
Dynamic light scattering measurements
The particle size of the free PTX-loaded PGG–PTX nano-
particles obtained directly from the nanoparticle formula-
tion was determined by DLS using a Zetasizer Nano-ZS 
(Malvern Instruments Inc, Malvern, UK) equipped with an 
He–Ne laser (4 mW, 633 nm) light source and 90° angle 
scattered light collection configuration. The solution of 
the free PTX-loaded PGG–PTX nanoparticles was further 
diluted to the final concentration of approximately 2 mg/mL 
and was allowed to equilibrate for 2 min at 25°C before 
the measurements. The hydrodynamic diameter of the free 
PTX-loaded PGG–PTX nanoparticles was calculated based 
on the Stokes–Einstein equation. Correlation function was 
curve fitted by cumulant method to calculate mean size 
and polydispersity index. All measurements were repeated 
three times, and mean particle size was presented as the 
average diameter with standard deviation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Maximum tolerated dose studies
MTD was defined as the dose that produced 15% weight loss. 
MTD for PTX-loaded PGG–PTX nanoparticles administered 
via tail vein injection was investigated in healthy BABL/c nude 
mice (20 ± 2 g). The nude mice were divided into four groups 
(n = 5), which were injected with: 1) saline as a control, 
2) 210 mg/kg of total PTX of PTX-loaded PGG–PTX nano-
particles, 3) 230 mg/kg of total PTX of PTX-loaded PGG–PTX 
nanoparticles, and 4) 250 mg/kg of total PTX of PTX-loaded 
PGG–PTX nanoparticles. Mice survival and variation in body 
weight were observed and recorded daily over 14 days.
Therapeutic efficacy experiments
Female athymic nude mice were randomly divided into 
four groups (n = 6). Each group was injected subcutaneously 
in their shoulders with 0.1 mL of suspension cells containing 
4 × 106 viable NCI-H460 human lung cancer cells. Tumors were 
allowed to grow until they reached an average volume of about 
100 mm3. Tumor size in mm3 was estimated from the formula 
(w2 × l)/2, where “l” is the longest diameter of the tumor and “w” 
is the diameter perpendicular to the   longest diameter measured in 
  millimeters. A single dose of 1) saline, 2) 50 mg/kg PTX formu-
lated in Cremophor–ethanol, 3) 180 mg/kg total PTX equivalent 
of PTX-loaded PGG–PTX nanoparticles, or 4) 230 mg/kg total 
PTX equivalent of PTX-loaded PGG–PTX nanoparticles in 
saline was administered intravenously(IV) via tail vein   injection. 
Body weight change and tumor volume of the mice were mea-
sured daily for the duration of the study until total tumor burden 
of the saline injection as a control reached 3000 mm3, at which 
time all the mice were terminated from the study.
statistics
The tumor volume data were shown as mean ± standard 
error of the mean. The statistical significance of differences 
in the data between two groups was calculated by means of 
repeated measures. The slope of the regression of log (tumor 
volume) on time was determined for each individual tumor 
and the mean of the slopes of all tumors within a group was 
compared using Student’s t-test. A value of P , 0.05 was 
considered statistically significant.
Results and discussion
Polymers have been extensively explored for drug delivery 
of PTX.4,7,13,14 Polymers can be used either as polymeric PTX 
micelles or polymer–PTX conjugates. Polymeric micelles 
employing di-block copolymers are an effective formulation 
to solubilize PTX. The formulation results in the formation 
of micellar nanoparticles, which are intended for tumor 
  passive targeting, known as enhanced permeability and 
retention effects.21,22 PTX conjugated onto PGG is another 
formulation. Previously, we reported the synthesis, charac-
terization, and in vitro evaluation of PGG–PTX conjugate.18 
The PGG–PTX conjugate intriguingly self-assembled into 
nanoparticles whose size remained in the range of 12–15 nm 
(volume) over the concentration range from 25 to 2000 µg/mL 
in saline.18 PGG–PTX conjugate was further demonstrated to 
possess superior in vivo antitumor efficacy19 and to exhibit pro-
longed half-life pharmacokinetics.20 Polymeric PTX micelles 
and PGG–PTX conjugate have their own unique properties.
In this study, we presented the feasibility of combining 
polymeric micelles and polymer conjugates into one nanopar-
ticle delivery system of PTX. The novel nanoparticle delivery 
system featured entrapped PTX and conjugated PTX. A sche-
matic formulation of PTX-loaded PGG–PTX nanoparticles is 
shown in Figure 1. The design of the nanoparticle formation 
was simple. A solution of free PTX in ethanol (5 mg/mL) 
was added to a solution of polymer–PTX conjugate in water 
(25/mL) while being stirred, and the nanoparticles were 
formed after the ethanol was slowly evaporated overnight. The 
percentage of PTX relative to PGG–PTX conjugate was 7.5% 
weight by weight. To our knowledge, this is the first polymeric 
nanoparticulate containing entrapped free PTX drug and 
conjugated PTX drug united into one delivery system.
Encapsulation of free PTX with PGG–PTX conjugate 
was demonstrated by comparing  1H-NMR spectra of free 
PTX in CD3OD, PGG–PTX conjugate in D2O, and PTX-
loaded PGG–PTX nanoparticles in CD3OD and D2O. 
1H-NMR   spectra of PTX in CD3OD (A), PGG–PTX conju-
gate in D2O (B), PTX-loaded nanoparticles in D2O (C), and 
CD3OD (D), respectively, are shown in Figure 2. When PTX 
was encapsulated inside the nanoparticles, the characteristic 
peaks of PTX were hardly seen in D2O due to their insufficient 
mobility in D2O. However, in CD3OD, resonance peaks corre-
sponding to the PTX were clearly observed. This observation 
was consistent with 1H-NMR studies of the other polymer 
micelles in D2O reported.23,24 The 1H-NMR results indicated 
that PTX was successfully entrapped into the hydrophobic 
inner core of the polymeric nanoparticles.
Further DLS and TEM studies confirmed the formation of 
PTX-loaded PGG–PTX nanoparticles. The average particle 
size and the unimodal size distribution of both PGG–PTX 
conjugate and PTX-loaded PGG–PTX were examined by 
DLS, and the results are illustrated in Figure 3(A) and (B). 
The Z-mean diameter of PGG–PTX conjugate in water was 
approximately 20 nm, with a narrow polydispersity index 
(PDI) of 0.27. The particle size of PGG–PTX conjugate in 
water was consistent with the previous study of the conjugate 
in saline, which was about 12–15 nm.18 The particle size International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 schematic of formation of free paclitaxel-loaded Pgg–PTX nanoparticles. 
Abbreviations: Pgg, poly(L-γ-glutamylglutamine); PTX, paclitaxel.
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Figure 2 A) 1h-NMr spectra of paclitaxel in cD3OD; B) Pgg–PTX nanoconjugate in D2O; C) paclitaxel-loaded Pgg–PTX nanoparticles in D2O; and D) paclitaxel-loaded 
Pgg–PTX nanoparticles in cD3OD.
Note: *Free paclitaxel protons. 
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Figure 3 The particle size distribution of Pgg–PTX nano-conjugate A) and paclitaxel-loaded Pgg–PTX nanoparticles B) measured by DLs. 
Abbreviations: d.nm; diameter in nanometers; DLs, dynamic light scattering; Pgg, poly(L-γ-glutamylglutamine); PTX, paclitaxel.
and distribution of free PTX-loaded nanoparticles in water 
were 270 nm and 0.08 PDI, respectively. Furthermore, TEM 
images of PGG–PTX conjugate and PTX-loaded nanoparticle 
exhibited a spherical shape of moderate uniform particle size, 
as shown in Figure 4(a) and (b). The particle size of PGG–
PTX conjugate observed by TEM was about 20 nm, which 
was consistent with the DLS data. However, particle size 
of PTX-loaded PGG–PTX nanoparticle observed by TEM 
was about 50 nm, which was smaller than that determined 
by DLS. We speculated that the particle size determined by 
DLS represents their hydrodynamic diameter, whereas that 
obtained by TEM is related to the collapsed micelles after 
water evaporation. The TEM diameter of the PTX-loaded 
nanoparticles was smaller than the DLS diameter.
To confirm the applicability of the free PTX-loaded 
PGG–PTX nanoparticles, the nanoparticles were investigated 
for antitumor activity in mouse-bearing human lung NCI-H460 
cancer models. Prior to antitumor efficacy study, MTD of the 
nanoparticles needed to be determined. With respect to PTX-
loaded PGG–PTX nanoparticles, MTD was defined as the dose 
that yielded 15% weight loss. The MTD studies for the PTX-
loaded nanoparticles were carried out in healthy BABL/c nude 
mice. The mice were divided into three experimental groups 
and one saline control group (n = 5 for each group). The mice 
of experimental groups were administered with a single IV tail 
vein injection of 1) 210 mg/kg, 2) 230 mg/kg, and 3) 250 mg/kg 
of total PTX of PTX-loaded PGG–PTX nanoparticles. Mice 
survival was observed, and their body weight change was 
measured and recorded daily for the duration of the study. No 
mice died during the MTD study period. The details of their 
body weight change are shown in Figure 5. When the doses 
of the PTX-loaded nanoparticles were administered, 5%–15% 
body weight loss was observed. The body weight of the healthy 
BABL/c nude mice was consistent with the escalation of the 
doses. On the basis of the results, MTD of the PTX-loaded 
nanoparticles was decided at 230 mg/kg of total PTX. With the 
MTD of the PTX-loaded nanoparticles, a study of antitumor 
efficacy was carried out on BABL/c nude mice bearing NCI-
H460 human lung cancer xenografts. The mice were randomly 
divided into two experimental groups (180 and 230 mg/kg of the 
total PTX equivalence of PTX-loaded nanoparticles), one posi-
tive control group (50 mg/kg of PTX), and one saline negative 
control group (n = 6 for each group). The mice received a single 
IV tail vein injection after 12 days of subcutaneous implantation 
with the   NCI-H460 human lung cancer cells when the mean 
tumor volume reached 100 mm3. The antitumor activity of the 
nanoparticles was compared with that of PTX and saline by 
measuring tumor volume and survival rates of the mice. Results 
of the efficacy study are shown in Figure 6. The results indicated 
that the PTX-loaded nanoparticles inhibited tumor growth. At 
the dose of 230 mg/kg of the total PTX equivalents, PTX-loaded 
nanoparticles showed stronger tumor regression with statisti-
cally significant differences compared with that of 50 mg/kg 
of PTX (P = 0.036), 180 mg/kg of the total PTX of the PTX-
loaded nanoparticles (P = 0.019), and saline (P = 0.006) after 
administration. However, it seemed that the PTX-loaded PGG–
PTX nanoparticles exhibited higher toxicity in mice-bearing 
human lung NCI-H460 cancer (Figure 6, bottom) compared 
with that of healthy mice (Figure 5) based on their body weight 
loss. Surprisingly, the dose of 180 mg/kg, PTX equivalents, of 
the nanoparticles appeared to lead to more weight loss than that 
of 230 mg/kg (Figure 6, bottom). No statistical significance of 
Figure 4 TeM micrograph of the Pgg–PTX nanoconjugates a) and paclitaxel–
loaded Pgg–PTX nanoparticles b). 
Abbreviations: Pgg, poly(L-γ-glutamylglutamine); PTX, paclitaxel; TeM, transmission 
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tumor inhibition was observed between 180 mg/kg of the total 
PTX of the PTX-loaded nanoparticles and 50 mg/kg of PTX 
(P = 0.934). The antitumor efficacy of 230 mg/kg of the total 
PTX of the novel PTX-loaded nanoparticles confirmed the 
feasibility of a dual PTX drug delivery system to be applicably 
useful for chemotherapy.
Conclusion
The results of this study contribute two important scientific 
issues. First, we provide the first and most simple method of 
forming nanoparticles featuring free PTX and conjugated 
PTX in the same drug delivery system. Second, these nano-
particles can effectively inhibit tumor growth. The versatility 
and potential of this dual drug system can be explored with 
different drugs for different indications. Developing novel 
and simple PTX-loaded PGG–PTX nanoparticles could have 
important implications in translational medicines.
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